AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 151 min read$PHVS

Lu Peng sold $602K of PHVS

Lu Peng (President) sold 15,000 shares of Pharvaris N.V. (PHVS) at $40.13 ($0.60M total) on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lu Peng
Published Sep 15, 2026, 6:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The disclosed sale is modest and likely already priced in; traders should focus on larger catalysts.

02

Market read

Primary insider sale with limited material impact; low trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 5/10Timing: filing date 2026-09-15

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is pre‑arranged and often non‑informative.

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

President Lu Peng sold 15,000 shares for $602K via a 10b5-1 plan, reducing his holdings to 65,179 shares.

Expected impact

minor downward pressure or flat price action

Evidence & confidence

The sale amount is modest relative to market cap and follows a pre‑arranged plan, limiting informational value.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

Limited to US biotech investors; no regional ripple.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be routine and unrelated to fundamentals; investors may ignore it.

Key entities

  • Company
    Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Insider
    Lu Peng

    President of Pharvaris, reporting a sale of 15,000 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PHVS insider trading history →

Related articles

SEP 12
$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

stocktwits.com2 min
SEP 10
$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

investing.com3 min
SEP 9
$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.

rttnews.com2 min